Investors are often guided by the idea of discovering ‘the next big thing’, even if that means buying ‘story stocks’ without any revenue, let alone profit. But the reality is that when a company loses money each year, for long enough, its investors will usually take their share of those losses. While a well funded company may sustain losses for years, it will need to generate a profit eventually, or else investors will move on and the company will wither away.
If this kind of company isn’t your style, you like companies that generate revenue, and even earn profits, then you may well be interested in Shanghai Allist Pharmaceuticals (SHSE:688578). Even if this company is fairly valued by the market, investors would agree that generating consistent profits will continue to provide Shanghai Allist Pharmaceuticals with the means to add long-term value to shareholders.
See our latest analysis for Shanghai Allist Pharmaceuticals
